Scinai Immunotherapeutics Secures $10 Million Equity Funding
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company engaged in the development of inflammation and immunology (I&I) biological products. Recently, the company revealed a significant advancement by entering into a Standby Equity Purchase Agreement (SEPA) for $10 million with YA II PN, Ltd., managed by Yorkville Advisors Global, LP. This agreement positions Scinai to optimize its capital resources effectively.
Details of the Standby Equity Purchase Agreement
The SEPA offers Scinai the right to sell up to $10 million worth of its American Depository Shares (ADSs) over a period of three years. Each ADS represents 4,000 ordinary shares. The agreement grants Scinai flexibility in deciding when and how much to sell, contingent upon the effectiveness of a registration statement with the Securities and Exchange Commission. Importantly, transactions will have a beneficial ownership cap of 9.99% of Scinai’s share capital, ensuring compliance with regulatory standards.
Pricing Dynamics and Investor Benefits
For investors, the acquisition price of the ADSs will be set at a 3% discount based on the lowest daily volume-weighted average price observed over the three trading days post-notification delivery by Scinai. This pricing approach gives exposure to advantageous market conditions while ensuring the company's operational strategies remain unhindered.
Strategic Financial Flexibility
Amir Reichman, the CEO of Scinai, emphasized the advantages of this strategic agreement, stating it provides a valuable means to access additional capital at a minimal discount, without the encumbrance of issuing warrants. This approach reinforces Scinai's autonomy in financial decisions, allowing it to seize opportunities for growth as they arise.
Future Use of Proceeds
Scinai plans to allocate the potential proceeds from the ADS offering under the SEPA towards enhancing its NanoAbs programs, supporting its contract development and manufacturing organization (CDMO) operations, and facilitating various corporate objectives including working capital, research and development, regulatory initiatives, and strategic investments.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is at the forefront of biopharmaceutical innovation, focusing on the development of cutting-edge therapeutics that address significant health challenges. The company operates two synergistic business divisions: one dedicated to the in-house development of I&I biological therapeutic products and the other providing a boutique CDMO service that includes drug development and clinical trial execution for emerging biotech projects.
Company Contact Information
For general inquiries, you can reach Scinai Immunotherapeutics at their dedicated phone line or through their investor relations contacts. They are committed to transparency and accessibility, fostering a solid communication channel with their stakeholders.
Frequently Asked Questions
What is the purpose of the Standby Equity Purchase Agreement?
The SEPA allows Scinai to sell ADSs to raise capital as needed, providing financial flexibility without mandatory commitments.
Who manages the fund involved in the SEPA?
YA II PN, Ltd., managed by Yorkville Advisors Global, LP, is the entity involved in this agreement.
What is the discount rate offered for the ADSs?
The purchase price for the ADSs includes a 3% discount, favorable for potential investors.
How will Scinai use the funds raised?
Funds will primarily support Scinai's NanoAbs development, CDMO services, and general operational needs.
What is the significance of the beneficial ownership cap?
The 9.99% cap ensures that Scinai remains compliant with regulatory requirements while maintaining investor interest.
